Calmare Therapeutics Inc. (CTTC) Financial Statements (2025 and earlier)

Company Profile

Business Address 1375 KINGS HIGHWAY EAST
FAIRFIELD, CT 06824
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5065774
Cash and cash equivalent5065774
Receivables332143216
Inventory, net of allowances, customer advances and progress billings   4,2784,360
Inventory   4,2784,360
Prepaid expense5814465✕
Prepaid expense and other current assets✕✕✕✕79
Other undisclosed current assets4,0284,227  
Total current assets:4,1694,3794,5444,730
Noncurrent Assets
Property, plant and equipment2436827
Other undisclosed noncurrent assets15151515
Total noncurrent assets:39512342
TOTAL ASSETS:4,2084,4304,5664,771
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,1933,9241,2752,580
Interest and dividends payable 988  
Employee-related liabilities50   
Accounts payable1,8951,3466921,806
Accrued liabilities2,2481,590583773
Debt3,7852,5372,4891,310
Derivative instruments and hedges, liabilities37537580120
Deferred revenue and credits    10
Other undisclosed current liabilities6,2015,2766,6664,556
Total current liabilities:14,55412,11210,5118,575
Noncurrent Liabilities
Long-term debt and lease obligation 6857 225
Long-term debt, excluding current maturities 6857 225
Total noncurrent liabilities: 6857 225
Total liabilities:14,62212,16810,5118,800
Equity
Equity, attributable to parent, including:(10,414)(7,738)(5,944)(4,029)
Preferred stock   61 
Common stock285259200152
Additional paid in capital48,61147,63546,07745,368
Accumulated deficit(59,371)(55,693)(52,282)(49,610)
Warrants and rights outstanding   8 
Other undisclosed equity, attributable to parent6161(8)61
Total equity:(10,414)(7,738)(5,944)(4,029)
TOTAL LIABILITIES AND EQUITY:4,2084,4304,5664,771

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)		8911,1918091,018
Cost of revenue
(Cost of Product and Service Sold)		(280)(441)(273)(366)
Other undisclosed gross profit  (146)(156)(106)
Gross profit:612604380546
Operating expenses(979)(1,181)(3,171)(3,707)
Other undisclosed operating loss(2,331)(1,653)  
Operating loss:(2,699)(2,230)(2,791)(3,161)
Nonoperating income
(Investment Income, Nonoperating)		  145954
Interest and debt expense(977)(1,096)(210)(83)
Loss from continuing operations before equity method investments, income taxes:(3,675)(3,312)(2,943)(3,190)
Other undisclosed income (loss) from continuing operations before income taxes (3)(99)270186
Loss from continuing operations:(3,678)(3,411)(2,672)(3,004)
Loss before gain (loss) on sale of properties:(3,678)(3,411)(2,672)(3,004)
Net loss available to common stockholders, diluted:(3,678)(3,411)(2,672)(3,004)

Comprehensive Income ($ in thousands)
Annual | Quarterly

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(3,678)(3,411)(2,672)(3,004)
Comprehensive loss, net of tax, attributable to parent:(3,678)(3,411)(2,672)(3,004)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: